Overview of the cardiovascular benefit with diabetic agents and novel combination products for type 2 diabetes.

Overview of the cardiovascular benefit with diabetic agents and novel combination products for type 2 diabetes. Am J Manag Care. 2017 Aug;23(13 Suppl):S241-S246 Authors: Morello CM Abstract Cardiovascular (CV) disease is commonly observed in individuals with type 2 diabetes (T2D) and is associated with significant morbidity and mortality. Diabetes medications can have substantial negative or beneficial CV effects in these patients. Thus far, specific glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors have been shown to have beneficial CV effects in persons with T2D. Clinical trials are ongoing to evaluate the CV effects of investigational and recently approved diabetes medications. Additional advances through novel combination products have been shown to improve medication adherence and patient convenience. Future studies will evaluate the long-term effects of these combination products in patients with T2D. PMID: 28978218 [PubMed - in process]
Source: The American Journal of Managed Care - Category: Health Management Authors: Tags: Am J Manag Care Source Type: research